勘误：RENATA研究——拉丁美洲前瞻性经验：在激素受体阳性转移性乳腺癌中使用哌柏西利治疗患者的临床结局——实际应用。
Erratum: RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
作者信息
Petracci Fernando, Abuin Gonzalo Gomez, Pini Alejandra, Chacón Matías
机构信息
Breast Cancer Department, Instituto Alexander Fleming and Sanatorio Las Lomas, Buenos Aires 1428, Argentina.
Oncology Service, Hospital Alemán, Buenos Aires 1428, Argentina.
出版信息
Ecancermedicalscience. 2020 Aug 7;14:1087. doi: 10.3332/ecancer.2020.1087. eCollection 2020.
Abstract
[This corrects the article on p. 1 in vol. 14.].
摘要
[这更正了第14卷第1页上的文章。]
相似文献
1
Erratum: RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.勘误：RENATA研究——拉丁美洲前瞻性经验：在激素受体阳性转移性乳腺癌中使用哌柏西利治疗患者的临床结局——实际应用。
Ecancermedicalscience. 2020 Aug 7;14:1087. doi: 10.3332/ecancer.2020.1087. eCollection 2020.
2
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.帕博西尼联合戈舍瑞林与卡培他滨用于激素受体阳性、HER2 阴性转移性乳腺癌绝经前妇女（KCSG-BR15-10）：一项多中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24.
3
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.在真实世界环境中，美国接受帕博西尼联合芳香化酶抑制剂或氟维司群治疗 HR+/HER2-晚期/转移性乳腺癌患者的治疗模式和临床结局：IRIS 研究结果。
Breast. 2019 Feb;43:22-27. doi: 10.1016/j.breast.2018.10.009. Epub 2018 Oct 20.
4
Correction to "Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results".《帕博西尼联合内分泌治疗在激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌中的有效性和安全性：真实世界结果》的勘误
Can J Hosp Pharm. 2022 Spring;75(2):128. doi: 10.4212/cjhp.v75i2.3285. Epub 2022 Apr 4.
5
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.帕博西尼联合内分泌治疗转移性乳腺癌患者的真实世界临床结局和毒性。
Breast Cancer Res Treat. 2019 Jul;176(2):429-434. doi: 10.1007/s10549-019-05176-1. Epub 2019 Mar 20.
6
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer.帕博西尼致不良反应的真实世界经验及激素受体阳性/HER2 阴性转移性乳腺癌患者全血细胞计数监测的依从性。
Clin Breast Cancer. 2019 Feb;19(1):e186-e194. doi: 10.1016/j.clbc.2018.09.002. Epub 2018 Sep 8.
7
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.帕博西尼处方模式的真实世界证据分析：美国社区肿瘤实践中批准上市后一年治疗晚期/转移性乳腺癌患者。
Breast Cancer Res. 2018 May 2;20(1):37. doi: 10.1186/s13058-018-0958-2.
8
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).帕博西尼联合氟维司群治疗激素受体阳性/人表皮生长因子受体2阴性晚期转移性乳腺癌女性患者：一项多中心、随机、安慰剂对照、III期研究（PALOMA-3）的详细安全性分析
Oncologist. 2016 Oct;21(10):1165-1175. doi: 10.1634/theoncologist.2016-0097. Epub 2016 Jul 1.
9
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.接受帕博西尼联合治疗的晚期/转移性乳腺癌女性的治疗满意度。
Future Oncol. 2019 Jan;15(2):141-150. doi: 10.2217/fon-2018-0531. Epub 2018 Sep 12.
10
Palbociclib in metastatic breast cancer: current evidence and real-life data.帕博西尼治疗转移性乳腺癌：当前证据与真实世界数据
Drugs Context. 2019 Jul 16;8:212579. doi: 10.7573/dic.212579. eCollection 2019.
引用本文的文献
1
Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer-A retrospective study.三阳性乳腺癌与HER2阳性乳腺癌的临床病理特征及预后分析——一项回顾性研究
Front Oncol. 2023 Jan 12;12:999894. doi: 10.3389/fonc.2022.999894. eCollection 2022.
Zotero 插件